Werewolf Therapeutics (HOWL) News Today $1.64 -0.03 (-1.80%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare ConferenceNovember 20 at 8:00 AM | globenewswire.comInnovative Cytokine Immunotherapy: Werewolf Therapeutics’ Pioneering Approach and Promising PipelineNovember 19 at 1:32 PM | markets.businessinsider.comWerewolf Therapeutics' (HOWL) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a report on Tuesday.November 19 at 8:22 AM | marketbeat.comResearch Analysts Offer Predictions for HOWL FY2024 EarningsNovember 14, 2024 | americanbankingnews.comFY2024 Earnings Estimate for HOWL Issued By Leerink PartnrsWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2024 earnings per share estimates for shares of Werewolf Therapeutics in a report issued on Monday, November 11th. Leerink Partnrs analyst D. Graybosch now forecasts that the comNovember 13, 2024 | marketbeat.comPromising Potential of Werewolf Therapeutics’ INDUKINE Platform Despite ChallengesNovember 13, 2024 | markets.businessinsider.comWerewolf Therapeutics Advances Innovative Cytokine TherapiesNovember 13, 2024 | markets.businessinsider.comBuy Rating for Werewolf Therapeutics: Strong Financial Position and Promising PipelineNovember 11, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for HOWL Q1 Earnings?Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Werewolf Therapeutics in a research report issued to clients and investors on Friday, November 8th. HC Wainwright analyst A. MaldonadoNovember 11, 2024 | marketbeat.comBuy Recommendation for Werewolf Therapeutics: Promising Developments in WTX-330 Clinical TrialsNovember 9, 2024 | markets.businessinsider.comWerewolf Therapeutics sees cash runway through 2Q26November 8, 2024 | markets.businessinsider.comWerewolf Therapeutics presents preclinical, clinical data on WTX-330November 8, 2024 | markets.businessinsider.comWerewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | markets.businessinsider.comWerewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingNovember 7, 2024 | globenewswire.comDark Wolf Nebula shows off a howling good view in awesome Halloween image (video)October 31, 2024 | msn.comLeonardo DiCaprio and Jane Goodall-Produced Movie ‘Howl’ Boarded by Pulsar Content, XYZ Films Ahead of AFM (EXCLUSIVE)October 31, 2024 | msn.comWerewolf Therapeutics announces addition of WTX-921 to pipelineOctober 31, 2024 | msn.comLeigh Whannell's Wolf Man Deviated From The Original Ryan Gosling Pitch, And The Writer/Director Told Me WhyOctober 22, 2024 | msn.comBank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ StocksOctober 19, 2024 | msn.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest UpdateWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) saw a significant decline in short interest in September. As of September 30th, there was short interest totalling 1,040,000 shares, a decline of 7.1% from the September 15th total of 1,120,000 shares. Currently, 3.4% of the company's stock are short sold. Based on an average daily volume of 184,400 shares, the days-to-cover ratio is currently 5.6 days.October 16, 2024 | marketbeat.comMillennium Management LLC Raises Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)Millennium Management LLC increased its stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) by 96.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,110,298 shares of the company's stock after purchasing an adOctober 16, 2024 | marketbeat.comWerewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingOctober 5, 2024 | finance.yahoo.comWerewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingOctober 4, 2024 | globenewswire.comRewilding eco-zealots have cried wolfSeptember 29, 2024 | yahoo.comRubric Capital Management LP Lowers Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)Rubric Capital Management LP trimmed its stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) by 17.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,333,893 shares of the company'sSeptember 21, 2024 | marketbeat.comWerewolf Therapeutics (NASDAQ:HOWL) Stock Price Down 3.6%Werewolf Therapeutics (NASDAQ:HOWL) Stock Price Down 3.6%September 13, 2024 | marketbeat.comWerewolf Therapeutics: A Buy Rating with Strong Upside Potential Amidst Market PullbacksSeptember 11, 2024 | markets.businessinsider.comWerewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | markets.businessinsider.comAnalysts Offer Predictions for Werewolf Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:HOWL)Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Werewolf Therapeutics in a research report issued to clients and investors on Monday, August 19th. Leerink Partnrs analyst D. Graybosch forecasts that the companAugust 22, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL) and Chimerix (CMRX)August 21, 2024 | markets.businessinsider.comBrokers Issue Forecasts for Werewolf Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:HOWL)Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities research analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for shares of Werewolf Therapeutics in a note issued to investors on Monday, August 19th. Leerink Partnrs analyst D. Graybosch expects that the company wAugust 20, 2024 | marketbeat.comBuy Rating Affirmed for Werewolf Therapeutics on Strong Candidate Progress and Promising Safety ProfilesAugust 10, 2024 | markets.businessinsider.comBuy Rating Affirmed: Werewolf Therapeutics’ Promising Pipeline and Financial HealthAugust 9, 2024 | markets.businessinsider.comHOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Beats Revenue for Q2 2024August 8, 2024 | investorplace.comWerewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 8, 2024 | globenewswire.com1,688,054 Shares in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Bought by Janus Henderson Group PLCJanus Henderson Group PLC acquired a new position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,688,054 shares of the company's stock, valued atAugust 2, 2024 | marketbeat.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 55.1% in JulyWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the recipient of a significant growth in short interest in July. As of July 15th, there was short interest totalling 1,050,000 shares, a growth of 55.1% from the June 30th total of 677,100 shares. Based on an average daily trading volume, of 313,000 shares, the short-interest ratio is presently 3.4 days. Currently, 3.5% of the shares of the company are sold short.July 27, 2024 | marketbeat.comWoman Captured Howling with Gigantic White Wolf in Beautiful FootageJuly 24, 2024 | msn.comWerewolf Therapeutics (NASDAQ:HOWL) Rating Reiterated by HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday.July 2, 2024 | marketbeat.comWerewolf Therapeutics (NASDAQ:HOWL) Given Market Outperform Rating at JMP SecuritiesJMP Securities restated a "market outperform" rating and set a $12.00 price target on shares of Werewolf Therapeutics in a report on Wednesday.June 26, 2024 | marketbeat.comWerewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomaJune 25, 2024 | globenewswire.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 26.1% in MayWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 469,100 shares, a growth of 26.1% from the May 15th total of 372,000 shares. Based on an average daily trading volume, of 188,100 shares, the days-to-cover ratio is presently 2.5 days. Approximately 1.6% of the shares of the stock are sold short.June 17, 2024 | marketbeat.comWerewolf Therapeutics (NASDAQ:HOWL) Given Outperform Rating at WedbushWedbush reaffirmed an "outperform" rating and set a $9.00 target price on shares of Werewolf Therapeutics in a research report on Monday.June 3, 2024 | marketbeat.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Sees Large Decline in Short InterestWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the recipient of a significant decline in short interest in May. As of May 15th, there was short interest totalling 372,000 shares, a decline of 10.3% from the April 30th total of 414,500 shares. Based on an average trading volume of 185,300 shares, the days-to-cover ratio is currently 2.0 days. Approximately 1.3% of the company's stock are short sold.June 3, 2024 | marketbeat.comWerewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid TumorsJune 1, 2024 | globenewswire.comWerewolf Therapeutics to Participate at the Jefferies Global Healthcare ConferenceMay 30, 2024 | globenewswire.comHowling II: Stirba – Werewolf Bitch Streaming: Watch & Stream Online via Amazon Prime VideoMay 26, 2024 | yahoo.comBuy Rating Justified by Werewolf Therapeutics’ Advancements in WTX-124 with Promising Efficacy and Safety ProfileMay 24, 2024 | markets.businessinsider.comCritical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To KnowMay 24, 2024 | markets.businessinsider.comWerewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual MeetingMay 23, 2024 | globenewswire.com Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. HOWL Media Mentions By Week HOWL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HOWL News Sentiment▼0.660.45▲Average Medical News Sentiment HOWL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HOWL Articles This Week▼72▲HOWL Articles Average Week Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Adicet Bio News Shattuck Labs News Xilio Therapeutics News Rani Therapeutics News Passage Bio News Curis News Nektar Therapeutics News Kodiak Sciences News ProQR Therapeutics News Immutep News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HOWL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HOWL Stock Alerts